QuantumScape Shares Rise 14% Ahead of Earnings Despite Revenue Concerns

QuantumScape (QS) shares rose 14% to $8.35 ahead of its April 29 earnings report, driven by short covering and speculative positioning. The company reported $19.5M in customer billings for 2025 and guided for $250M-$275M in adjusted EBITDA losses in 2026, despite having no product revenue in 2025 and insider share sales.

By David Moadel Thu, April 23, 2026 at 5:00 PM GMT+3 4 min read · Yahoo Finance · April 23, 2026, 14:00 UTC

QuantumScape Shares Rise 14% Ahead of Earnings Despite Revenue Concerns

Tickers: $QS

Topics: analyst predictions pre-earnings speculation QuantumScape short covering stock price movement

Read the full article at Yahoo Finance

More World news

Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC
CorMedix Reports Q3 2026 Results Amid DefenCath Pricing Transition and Heron Therapeutics Acquisition Plans Motley Fool · November 12, 2026, 17:40 UTC